An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine

Veterinary Parasitology

Volumn 100, Issue 1-2, 2001, Pages 87-103

  Gradoni, L ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Dog; Immune response; L. major; Leishmania infantum; Leishmaniasis; Vaccine

Indexed keywords

ANTIGEN ENCODING DNA PLASMID; CD4 ANTIGEN; DNA; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 4; LEISHMANIA VACCINE; LIVE RECOMBINANT BACTERIUM EXPRESSING LEISHMANIA ANTIGEN; LIVE VACCINE; PURIFIED LEISHMANIA FRACTION; RECOMBINANT LEISHMANIA ANTIGEN; UNCLASSIFIED DRUG;

BONE MARROW; BRAZIL; CLINICAL TRIAL; CONFERENCE PAPER; EVALUATION; HUMAN; IMMUNE RESPONSE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LIVER; MACROPHAGE ACTIVATION; NONHUMAN; PROVOCATION TEST; RESERVOIR; RETICULOENDOTHELIAL SYSTEM; SPLEEN; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS; ZOONOSIS;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; DISEASE RESERVOIRS; DOG DISEASES; DOGS; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; PROTOZOAN VACCINES;

EID: 0035850549     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4017(01)00486-1     Document Type: Conference Paper

References (91)

1. Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice
2. Subunit vaccination of mice against New World cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants
3. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response
4. Controlled field trials of a vaccine against New World cutaneous leishmaniasis
5. New strategies for control forum: Reservoir control
6. New perspectives on a subclinical form of visceral leishmaniasis
7. IL-2. A cofactor for induction of activated macrophage resistance to infection
8. Canine leishmaniasis: Identification of asymptomatic carriers by polymerase chain reaction and immunoblotting
9. Leishmaniasis in Tuscany (Italy): VIII. Human population response to leishmanin in the focus of Monte Argentario (Grosseto) and epidemiological evaluation
10. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs
11. Molecular cloning of the major surface antigen of Leishmania
12. The immunology of canine leishmaniasis: Strong evidence for a developing disease spectrum from asymptomatic dogs
13. Immunotherapy with live BCG plus heat-killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients
14. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis
15. Effective immunization against cutaneous leishmaniasis with recombinant bacillus Calmette-Guérin expressing the Leishmania surface proteinase gp63
16. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis
17. Double targeted gene replacement for creating null mutants
18. Age, acquired immunity and the risk of visceral leishmaniasis: A prospective study in Iran
19. Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum
20. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites
21. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil
22. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production
23. Vaccination trial against canine visceral leishmaniasis
24. The logic of visceral leishmaniasis control
25. Preparation and evaluation of Leishmania vaccines in Iran for the control of kala-azar
26. Dichotomy of the T-cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis absence or scarcity of Th1 activity is associated with severe infections
27. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis
28. Interleukin 10 production correlates with pathology in human Leishmania donovani infections
29. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum
30. Epizootiology of canine leishmaniasis in southern Europe
31. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment
32. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
33. DNA vaccines immunology, application, and optimization
34. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1-type of immune response
35. Therapy of murine cutaneous leishmaniasis by DNA vaccination
36. Interleukin 2 is necessary for progression of leishmaniasis in susceptible murine hosts
37. Potential role for interleukin 10 in the immunosuppression associated with kala-azar
38. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
39. Dichotomy of the human T-cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis
40. + T-cells in intracellular infections in human: Leishmania as an example
41. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
42. T-cell response in human leishmaniasis
43. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients
44. Ecologie des leishmaniases dans le sud de la France. 10. Les formes evolutives de la leishmaniase viscèrale canine
45. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes
46. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice
47. Susceptibility to infectious diseases: Leishmania as a paradigme
48. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis
49. The strange case of Leishmania chagasi
50. Phases I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs
51. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library
52. Vaccine trial against canine visceral leishmaniasis in the Islamic Republic of Iran
53. Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus
54. Leishmania infantum, the aetiologic agent of American visceral leishmaniasis (AVL)
55. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran
56. Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens
57. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy
58. Expression cloning of a protective Leishmania antigen
59. Vaccination of vervet monkeys against cutaneous leishmaniasis using recombinant Leishmania 'major surface glycoprotein' (gp63)
60. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum
61. Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction
62. Leishmaniasis in Tuscany (Italy): (VI) canine leishmaniasis in the focus of Monte Argentario (Grosseto)
63. The regulation of immunity to Leishmania major
64. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment
65. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification
66. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection
67. Human T cell responses to gp63, a surface antigen of Leishmania
68. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
69. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
70. + cells
71. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
72. Experience of antileishmaniasis vaccinations with cultures of Leishmania tropica major grown in various types of media
73. Advances in vaccine adjuvants
74. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1-type of immune response but does not protect against infection
75. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
76. LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
77. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection
78. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine
79. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
80. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice
81. Development of a safe live Leishmania vaccine line by gene replacement
82. Safety and immunogenicity of a killed Leishmania amazonensis (L.) vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial
83. Characterization of T cell responses to purified Leishmania antigens in subjects infected with Leishmania chagasi
84. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
85. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
86. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
87. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice
88. Development of a storable Leishmania tropica vaccine: Field testing with frozen promastigotes
89. Genetic vaccination against leishmaniasis
90. -)